Remove Bioassay Remove Development Remove Drug Delivery Remove Licensing
article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. Their capacity, which facilitates the delivery of larger mRNAs and the co-delivery of multiple RNAs, enables new therapeutic mechanisms.

Bioassay 130
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.